926
Views
25
CrossRef citations to date
0
Altmetric
Original

The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells

, , &
Pages 151-159 | Received 16 Sep 2007, Accepted 04 Dec 2007, Published online: 09 Jul 2009

References

  • Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295–1302
  • Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: Role of P-glycoproein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216–237
  • Pirity M, Hever-Szabo A, Venetianer A. Overexpression of P-glycoprotein in heat- and/or drug-resistant hepatoma variants. Cytotechnology 1996; 19: 207–214
  • Ji BS, He L, Liu GQ. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Life Sci 2005; 77: 2221–2232
  • Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3: 487–497
  • Hildebrandt B, Wust P, Ahlers O, Diening A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33–56
  • Wu C. Heat shock transcription factors: Structure and regulation. Ann Rev Cell Dev Biol 1995; 11: 441–469
  • Agashe VR, Hartl FU. Roles of molecular chaperones in cytoplasmatic protein folding. Sem Cell Dev Biol 2000; 11: 15–25
  • Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS. Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 1998; 30: 87–92
  • Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Marui N, Yoshida M, Sakai T, Nishino H, Aoike A, Kawai K. Flavonoids inhibit the expression of heat shock proteins. Cell Struct Funct 1990; 15: 393–401
  • Matsuda K, Nakagawa SY, Nakano T, Asaumi J, Jagetia GC, Kawasaki S. Effects of KNK437 on heat-induced methylation of histone H3 in human oral squamous cell carcinoma cells. Int J Hyperthermia 2006; 22: 729–735
  • Coss RA. Inhibiting induction of heat shock proteins as a strategy to enhance cancer therapy. Int J Hyperthermia 2005; 21: 695–701
  • Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Therapeut 2001; 90: 157–177
  • Perez-Vizcaino F, Duarte J, Andriantsitohaina R. Endothelial function, & cardiovascular disease: Effects of quercetin and wine polyphenols. Free Rad Res 2006; 40: 1054–1065
  • Le Marchand L. Cancer preventive effects of flavonoids–A review. Biomed Pharmacother 2002; 56: 296–301
  • Murota K, Terao J. Antioxidative flavonoid quercetin: Implication of its intestinal absorption and metabolism. Arch Biochem Biophys 2003; 417: 12–17
  • Dihal AA, Woutersen RA, van Ommen B, Rietjens IM, Stierum RH. Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2. Cancer Lett 2006; 238: 248–259
  • Jakubowicz-Gil J, Paduch R, Piersiak T, Głowniak K, Gawron A, Kandefer-Szerszeń M. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol 2005; 69: 1343–1350
  • Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 2005; 272: 4725–4740
  • Piantelli M, Tatone D, Castrilli G, Savini F, Maggiano N, Larocca LM, Ranelletti FO, Natali PG. Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res 2001; 11: 469–476
  • Asea A, Ara G, Teicher BA, Stevenson MA, Calderwood SK. Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 2001; 17: 347–356
  • Debes A, Oerding M, Willers R, Göbel U, Wessalowski R. Sensitization of human Ewing's tumor cells to chemotherapy and heat treatment by the bioflavonoid quercetin. Anticancer Res 2003; 23: 3359–3366
  • Jin J, Wang FP, Wei H, Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 2005; 55: 179–188
  • Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH, Liu JM. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res 2005; 52: 376–385
  • Lu HJ, Guo CB, Jin XQ, Wang LH. Influence of heat shock on expression of HSP70 in human glioma cells. Chin J Cancer Prev Treat 2005; 12: 1606–1608
  • Krishan A, Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res 1980; 40: 3895–3900
  • Kudo M, Naito Z, Yokoyama M, Asano G. Effects of quercetin and sunphenon on responses of cancer cells to heat shock damage. Exp Mol Pathol 1999; 66: 66–75
  • Jakubowicz-Gil J, Pawlikowska-Pawlega B, Piersiak T, Pawelec J, Gawron A. Quercetin suppresses heat shock-induced nuclear translocation of Hsp72. Folia Histochem Cytobiol 2005; 43: 123–128
  • Jakubowicz-Gil J, Rzymowska J, Gawron A. Quercetin, apoptosis, heat shock. Biochem Pharmacol 2002; 64: 1591–1595
  • Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med 1999; 31: 261–271
  • Hosokawa N, Hirayoshi K, Kudo H, Takechi H, Aoike A, Kawai K, Nagata K. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol Cell Biol 1992; 12: 3490–3498
  • Hansen PK, Oesterreich S, Lemieux P, Sarge KD, Fuqua SA. Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem Biophys Res Commun 1997; 239: 851–856
  • Nagasaka Y, Nakamura K. Modulation of the heat-induced activation of mitogen-activated protein (MAP) kinase by quercetin. Biochem Pharmacol 1998; 56: 1151–1155
  • Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia - A review. Int J Hyperthermia 1997; 13: 439–457
  • Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance for clinical hyperthermia. Int J Hyperthermia 1995; 11: 459–488
  • Kampinga HH. Hyperthermia, thermotolerance and topoisomerase II inhibitors. Br J Cancer 1995; 72: 333–338
  • Oh HJ, Chen X, Subjeck JR. Hsp 110 protects heat-denaturated proteins and confers cellular thermoresistance. J Biol Chem 1997; 272: 31636–31640
  • Douwes F, Bogovic J, Douwes O, Migeod F, Grote C. Whole-body hyperthermia in combination with platimum-containing drugs in patients with recurrent ovarian cancer. Int J Clin Oncol 2004; 9: 85–91
  • Westermann AM, Grosen EA, Katschinski DM, Jäger D, Rietbroek R, Schink JC, Tiggelaar CL, Jäger E, Zum Vörde sive Vörding P, Neuman A, et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovavian cancer. Eur J Cancer 2001; 37: 1111–1117
  • Stein U, Rau B, Wust P, Walther W, Schlag PM. Hyperthermia for treatment of rectal cancer: Evaluation for induction of multidrug resistance gene (mdr1) expression. Int J Cancer 1999; 80: 5–12
  • Tang WB, Ma PQ, Zeng WT, Zhu KL, Yang W. An experimental study on the effect of hyperthermia and chemotherapy combined with quercetin on liver hepatocar cinoma HepG2 cells. Cancer Res Clin 2006; 18: 77–80
  • Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer 2002; 98: 291–296
  • Komdeur R, Plaat BE, Hoekstra HJ, Molenaar WM, Hollema H, van den Berg E, Mastik MF, van der Graaf WT. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 2001; 91: 1940–1948
  • Coss RA, Dewey WC, Bamburg JR. Effects of hyperthermia on dividing Chinese hamster ovary cells and on microtubules in vitro. Cancer Res 1982; 42: 1059–1071
  • van Zanden JJ, van der Woude H, Vaessen J, Usta M, Wortelboer HM, Cnubben NH, Rietjens IM. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 2007; 74: 345–351
  • Ferry DR, Smith A, Malkhandi J, Fyfe DW, de Takats PG, Anderson D, Baker J, Kerr DJ. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996; 2: 659–668
  • Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 2005; 17: 86–95

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.